Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01029002 · ClinicalTrials.gov registry record · Phase 3
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
A Phase 3 study of Proteinuria and Chronic Renal Insufficiency, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT01029002 is a Phase 3 study of Proteinuria and Chronic Renal Insufficiency that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 74 participants, below the 199-participant average among 10 other Proteinuria trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01029002, a Phase 3 study of Proteinuria and Chronic Renal Insufficiency, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized clinical trial to determine if vitamin D repletion in CKD (Chronic Kidney Disease) patients with low vitamin D levels will decrease proteinuria, a marker of kidney damage.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Vitamin D
Study Locations (1)
New York
- Montefiore medical center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2009-10 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01029002
The ClinicalTrials.gov registry entry for NCT01029002 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 10 other Proteinuria trials with a reported enrollment target (63% lower). The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Proteinuria appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01029002 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01029002 about?
NCT01029002 is a clinical study titled "The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease". A randomized clinical trial to determine if vitamin D repletion in CKD (Chronic Kidney Disease) patients with low vitamin D levels will decrease proteinuria, a marker of kidney damage.
What is the current status of trial NCT01029002?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 74 participants. The study started on 2009-10. Estimated completion is 2014-06.
What conditions does trial NCT01029002 study?
This clinical trial studies the following conditions: Proteinuria, Chronic Renal Insufficiency.
What interventions are being tested in trial NCT01029002?
The interventions under investigation include: Placebo (OTHER), Vitamin D (DRUG).
Who is sponsoring clinical trial NCT01029002?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01029002 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proteinuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
COMPLETED · Phase 3
-
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
RECRUITING · Phase 2
-
Proteinuria in Pre and Post Transplant
RECRUITING
-
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.